Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could ...

Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 ...

4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...

Pterygium thickness did not meaningfully correlate with keratometry, astigmatism, irregularity indices, or most HOA metrics, suggesting depth contributes less to optical degradation than planar extent ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm ...

To explore what the veligrotug approval means for patients and practice, Ophthalmology Times posed the same questions to several TED specialists, including the following: Raymond S. Douglas, MD, PhD, ...

An offline, point-of-care algorithm on a smartphone fundus camera generated disease-specific outputs without cloud connectivity, addressing a major deployment barrier in low-resource screening ...

Digital Edition | Journals | Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Bascom Palmer Eye Institute leads ophthalmology rankings for the 22nd year, highlighting its consistent excellence in patient care. U.S. News & World Report evaluates hospitals across 15 specialties, ...

Ocular Surface Disease | Clinical | Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

FDA labeling covers active and chronic TED, addressing a major evidentiary gap left by prior IGF-1R inhibition programs that primarily enrolled active disease populations. Two pivotal phase 3 trials ...